Bioprogress BPRG - Serious Investors Only (Moderated)

To put an end to the argument about how many tablets one machine can produce, I found this:

"The initial TABWRAP® machine design output is 100,000 tablets per hour
which produces an average annual tablet output of 336m tablets per machine."
Source: Original CS BN.

Now, look at this:

"RT certainly had no intention of imparting any sensitive information to me nor was I expecting him to. He did however take great pains to make it clear, as he had at the AGM, that BioP model of selling lots of machines and making a royalties on film sales was dodos-ville ! The new model is to sell directly- made or indirectly-made value-added product systems where the technology is part of the product sell in niche markets where the end supplier makes a healthy margin and can afford to let BioP take its proper cut.

This includes the four 'block-buster' products referred to on the Website from the TTPs. Some of these products may only have 200,000 end-users worldwide. Therefore, 'blockbuster' does not refer to number of products/doses or number of users but to value of sales. This avoids trying to sell into price-sensitive high-volume but low margin markets where cost of goods are under continual pressure and where normal capex spend is no more that $50k (on gelatin coating machines). In these markets every $ increase in spend decreases more than proportionally profit whereas in niche, high-margin markets (where a system adds to the product benefit) the cost is part of the product price and offering and therefore adds to revenue rather than cost."
Source:

So let's assume that those 200,000 users take 1 pill per day so that's 73m tablets annually.

That would mean that this one Tabwrap machine is capable of supporting 4.6 such blockbuster deals. Okay, it hard to know the number of end users for each of the blockbuster products so the 4.6 is not reasonable so lets just cut it down to 2 blockbuster deals and some Dexo products with a total of 336m annual tablets.

The point I'm trying to make is that the capacity of this one machine is sufficient to bring great fortunes to bprg. If and when needed, additional capacity or technology transfer direct to the pharma can be planned.

And this is just Tabwrap. We're due to hear more from FMC in the next week or so.